ECSP066391A - [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia - Google Patents

[1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia

Info

Publication number
ECSP066391A
ECSP066391A EC2006006391A ECSP066391A ECSP066391A EC SP066391 A ECSP066391 A EC SP066391A EC 2006006391 A EC2006006391 A EC 2006006391A EC SP066391 A ECSP066391 A EC SP066391A EC SP066391 A ECSP066391 A EC SP066391A
Authority
EC
Ecuador
Prior art keywords
treatment
chichophrenia
naftiridin
onas
related compounds
Prior art date
Application number
EC2006006391A
Other languages
English (en)
Inventor
Joseph Thomas Repine
Jerry Clark
Jamie Davis
David Favor
Lorraine Fay
Lloyd Franklin
Kevin Henegar
Douglas Johnson
Brian Nichelson
Ligong Ou
Michael Walters
Andrew David White
Zhijian Zhu
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34216117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066391(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ECSP066391A publication Critical patent/ECSP066391A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere a compuestos de la fórmula 1 en la que G, A, Z, Q, X, Y y R1 y R2 se definen como en la memoria descriptiva, a composiciones farmacéuticas que los contienen y a su uso en el tratamiento de trastornos del sistema nervioso central y de otros trastornos.
EC2006006391A 2003-08-22 2006-02-22 [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia ECSP066391A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49737003P 2003-08-22 2003-08-22

Publications (1)

Publication Number Publication Date
ECSP066391A true ECSP066391A (es) 2006-08-30

Family

ID=34216117

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006391A ECSP066391A (es) 2003-08-22 2006-02-22 [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia

Country Status (35)

Country Link
US (3) US7160888B2 (es)
EP (1) EP1660497A1 (es)
JP (1) JP4034811B2 (es)
KR (2) KR100801794B1 (es)
CN (1) CN100422181C (es)
AP (1) AP2006003525A0 (es)
AR (1) AR045386A1 (es)
AU (1) AU2004266191B2 (es)
BR (1) BRPI0413860A (es)
CA (1) CA2538915C (es)
CR (2) CR8254A (es)
CU (1) CU23464B7 (es)
EA (1) EA009645B1 (es)
EC (1) ECSP066391A (es)
GE (1) GEP20084447B (es)
GT (1) GT200500007A (es)
HN (1) HN2004000319A (es)
IL (1) IL173439A0 (es)
IS (1) IS8267A (es)
MA (1) MA28003A1 (es)
ME (1) MEP45308A (es)
MX (1) MXPA06002070A (es)
MY (1) MY140693A (es)
NL (1) NL1026892C2 (es)
NO (1) NO20060324L (es)
NZ (1) NZ545078A (es)
OA (1) OA13238A (es)
PA (1) PA8609701A1 (es)
PE (1) PE20051039A1 (es)
RS (1) RS20060129A (es)
TN (1) TNSN06063A1 (es)
TW (1) TWI298327B (es)
UA (1) UA82541C2 (es)
WO (1) WO2005019215A1 (es)
ZA (1) ZA200601526B (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
ES2323451T7 (es) * 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
EP2204363A1 (en) * 2004-06-08 2010-07-07 NSAB, Filial af NeuroSearch Sweden AB, Sverige New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
MXPA06013944A (es) 2004-06-08 2007-10-08 Neurosearch Sweden Ab Nuevas fenilpiperidinas/piperazinas disustituidas como moduladores de la neurotransmision de dopamina.
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
FR2877005A1 (fr) * 2004-10-22 2006-04-28 Bioprojet Soc Civ Ile Nouveaux derives d'arylpiperazine
WO2006081289A2 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
WO2006090272A1 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia
WO2006103559A1 (en) * 2005-04-01 2006-10-05 Warner-Lambert Company Llc Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
CN101189228A (zh) * 2005-04-08 2008-05-28 辉瑞产品有限公司 用作i型甘氨酸转运抑制剂的二环[3.1.0]杂芳酰胺
RU2402549C3 (ru) * 2005-04-14 2022-03-10 Оцука Фармасьютикал Ко., Лтд. Пиперазин-замещенные бензотиофены для лечения психических расстройств
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI329641B (en) 2005-08-31 2010-09-01 Otsuka Pharma Co Ltd (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
CN102746298A (zh) 2005-10-07 2012-10-24 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
CA2627779A1 (en) * 2005-10-31 2007-05-10 Pfizer Products Inc. Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1h-[1,8]naphthyridin-2-one
US7935706B2 (en) 2006-02-23 2011-05-03 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
WO2007116265A1 (en) * 2006-03-31 2007-10-18 Pfizer Products Inc. Process for making a tetrahydro-pyridoazepin-8-one compound
WO2007136790A2 (en) 2006-05-18 2007-11-29 Mannkind Corporation Intracellular kinase inhibitors
WO2008032162A1 (en) * 2006-09-15 2008-03-20 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
US20100093738A1 (en) * 2006-10-06 2010-04-15 Basf Se Fungicidal Compounds and Fungicidal Compositions
WO2008047883A1 (en) * 2006-10-13 2008-04-24 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophenes for treatment of mental disorders
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
WO2008084324A1 (en) * 2007-01-04 2008-07-17 Pfizer Products Inc. Naphthyridinone compound
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
CL2008001002A1 (es) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
NZ582124A (en) * 2007-05-21 2012-07-27 Reviva Pharmaceuticals Inc Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
TW200904446A (en) * 2007-05-30 2009-02-01 Wyeth Corp Antidepressant heteroaryl derivatives of heterocycle-fused benzodioxans
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
MX2010006111A (es) 2007-12-18 2010-06-25 Actelion Pharmaceuticals Ltd Derivados de 5-aminociclilmetil-oxazolidin-2-ona y su uso como antibacteriales.
JP2011529090A (ja) 2008-07-28 2011-12-01 江蘇国華投資有限公司 アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
EP3085699B1 (en) 2008-07-31 2022-03-02 Firmenich Incorporated Processes for making sweet taste enhancers
KR101297450B1 (ko) 2008-12-12 2013-08-20 액테리온 파마슈티칼 리미티드 5-아미노-2-(1-하이드록시-에틸)-테트라하이드로피란 유도체
CN102341394B (zh) * 2009-01-23 2015-04-15 武田药品工业株式会社 聚(adp-核糖)聚合酶(parp)抑制剂
WO2010099502A1 (en) * 2009-02-26 2010-09-02 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
HRP20171415T4 (hr) 2009-06-25 2023-03-03 Alkermes Pharma Ireland Limited Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja
WO2010151711A1 (en) 2009-06-25 2010-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds
NZ603268A (en) 2010-05-04 2015-02-27 Alkermes Pharma Ireland Ltd Process for synthesizing oxidized lactam compounds
WO2011163594A2 (en) 2010-06-24 2011-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
WO2012003418A2 (en) * 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine d2 receptors
CN103261167B (zh) 2010-12-17 2016-05-04 霍夫曼-拉罗奇有限公司 取代的6，6-稠合含氮杂环化合物及其用途
PL3156056T3 (pl) 2011-03-18 2024-04-29 Alkermes Pharma Ireland Limited Kompozycje farmaceutyczne zawierające estry sorbitanu
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
NZ722096A (en) 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
NZ630703A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising glycerol esters
JP6333802B2 (ja) 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
JP6471089B2 (ja) 2012-03-19 2019-02-13 アルカームス ファーマ アイルランド リミテッド 脂肪酸エステルを含む医薬組成物
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 併用療法のための医薬組成物
WO2013169964A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
AU2013349388B2 (en) 2012-09-19 2018-06-28 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
RU2688233C2 (ru) 2014-03-20 2019-05-21 Алкермес Фарма Айэленд Лимитед Препараты арипипразола, имеющие повышенные скорости впрыска
CN104785295B (zh) * 2015-03-18 2018-03-06 杭州创培信息科技有限公司 一种高选择性多巴胺铂炭催化剂的制备方法
HK1255074A1 (zh) 2015-07-01 2019-08-02 Crinetics Pharmaceuticals, Inc. 生长抑素调节剂及其用途
CN113750101A (zh) 2015-12-10 2021-12-07 Ptc医疗公司 用于治疗亨廷顿病的方法
CN106242934A (zh) * 2016-07-26 2016-12-21 云南民族大学 一种酮的β‑位C‑H键乙酰氧化合成方法
US11407753B2 (en) * 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
CA3067591A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
EP3645121B8 (en) 2017-06-28 2025-06-18 PTC Therapeutics, Inc. Methods for treating huntington's disease
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CA3093189A1 (en) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
KR20210005559A (ko) 2018-03-27 2021-01-14 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
LT3814357T (lt) 2018-06-27 2024-06-25 Ptc Therapeutics, Inc. Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui
MX2021001193A (es) 2018-08-07 2021-04-28 Firmenich Incorporated 2,2-dioxidos de 4-amino-1h-benzo[c][1,2,6]tiadiazina 5-sustituidos y formulaciones y usos de los mismos.
BR112021002298A2 (pt) 2018-08-13 2021-05-04 F. Hoffmann-La Roche Ag compostos heterocíclicos como inibidores da monoacilglicerol lipase
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
BR112022002698A2 (pt) 2019-08-14 2022-07-19 Incyte Corp Compostos de imidazolil pirimidinilamina como inibidores de cdk2
PH12022550339A1 (en) 2019-09-12 2023-03-13 Hoffmann La Roche 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN114634479B (zh) * 2020-12-16 2025-02-07 北京盈科瑞创新药物研究有限公司 一种派嗪衍生物、其制备方法及应用
US20240217977A1 (en) * 2021-03-31 2024-07-04 Blueprint Medicines Corporation Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
EP4493551A1 (en) 2022-03-14 2025-01-22 Slap Pharmaceuticals LLC Multicyclic compounds
WO2023186023A1 (zh) * 2022-03-30 2023-10-05 苏州旺山旺水生物医药股份有限公司 一类n-取代的喹啉酮化合物、其制备方法和用途
CN114805081B (zh) * 2022-05-20 2024-09-24 都创(上海)医药开发有限公司 一种基于微通道连续流技术快速制备1-萘胺的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5649361A (en) 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPH07165720A (ja) * 1988-10-31 1995-06-27 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
HU207310B (en) 1988-12-02 1993-03-29 Pfizer Process for producing aryl-piperidine derivatives
ATE126512T1 (de) 1989-05-19 1995-09-15 Hoechst Roussel Pharma N-(aryloxyalkyl)heteroarylpiperidine und - heteroarylpiperazine, verfahren zu ihrer herstellung und ihre verwendung als medikamente.
US5350747A (en) 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
FI920023A7 (fi) * 1989-07-07 1992-01-03 Pfizer Heteroaryylipiperatsiiniyhdisteet antipsykootteina
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
AU645681B2 (en) 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
IE914218A1 (en) 1991-09-11 1993-03-24 Mcneilab Inc Novel 4-arylpiperazines and 4-arylpiperidines
US5206366A (en) 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
WO1994013676A1 (en) 1992-12-17 1994-06-23 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
RU2130453C1 (ru) 1992-12-17 1999-05-20 Пфайзер Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, способ лечения, промежуточный продукт
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
JP2862374B2 (ja) 1992-12-17 1999-03-03 フアイザー・インコーポレイテツド Ｃｒｆアンタゴニスト活性を有するピラゾール及びピラゾロピリミジン
FR2699918B1 (fr) 1992-12-30 1995-03-17 Pf Medicament Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments.
JPH07247271A (ja) * 1994-01-21 1995-09-26 Otsuka Pharmaceut Co Ltd ３，４−ジヒドロカルボスチリル誘導体
FR2731222A1 (fr) 1995-03-02 1996-09-06 Pf Medicament Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
JP2987484B2 (ja) * 1995-03-16 1999-12-06 大塚製薬 株式会社 カルボスチリル誘導体の製造方法
JP2900130B2 (ja) * 1995-03-16 1999-06-02 大塚製薬株式会社 カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
AU6517196A (en) 1995-07-13 1997-02-10 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
WO1997014419A1 (en) 1995-10-20 1997-04-24 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
JPH09241161A (ja) 1996-03-08 1997-09-16 Nippon Shinyaku Co Ltd 医 薬
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
FR2761071B1 (fr) 1997-03-20 1999-12-03 Synthelabo Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique
FR2769912B1 (fr) 1997-10-16 2000-03-10 Pf Medicament Nouveaux derives de la 3-oxo- (2h)-1,2,4 triazine leur preparation et leur application en therapeutique humaine
DE19747063A1 (de) 1997-10-24 1999-04-29 Basf Ag 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung
US6267784B1 (en) 1998-05-01 2001-07-31 Benz Research And Development Corporation Intraocular lens and haptics made of a copolymer
US6844344B2 (en) 1999-12-20 2005-01-18 Eli Lilly And Company Benzofuran derivatives
DE10041574A1 (de) 2000-08-24 2002-03-07 Merck Patent Gmbh Chromenonderivate
WO2002048105A2 (en) 2000-11-16 2002-06-20 Wyeth Aryloxy piperidinyl derivatives for the treatment of depression
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
DK1399438T3 (da) 2001-06-29 2006-04-18 Lundbeck & Co As H Hidtil ukendte heteroarylderivater samt fremstilling og anvendelse heraf
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Also Published As

Publication number Publication date
RS20060129A (sr) 2008-06-05
JP2007503386A (ja) 2007-02-22
BRPI0413860A (pt) 2006-10-24
JP4034811B2 (ja) 2008-01-16
US20060287310A1 (en) 2006-12-21
NO20060324L (no) 2006-05-18
MA28003A1 (fr) 2006-07-03
KR100765668B1 (ko) 2007-10-10
US20060287309A1 (en) 2006-12-21
CU23464B7 (es) 2009-12-17
MY140693A (en) 2010-01-15
PA8609701A1 (es) 2005-05-24
US20050043309A1 (en) 2005-02-24
CR8254A (es) 2006-10-17
NL1026892A1 (nl) 2005-02-28
NZ545078A (en) 2009-09-25
GEP20084447B (en) 2008-08-10
AU2004266191B2 (en) 2009-11-26
CA2538915C (en) 2010-06-15
EP1660497A1 (en) 2006-05-31
UA82541C2 (uk) 2008-04-25
MXPA06002070A (es) 2006-05-19
AP2006003525A0 (en) 2006-02-28
TW200524938A (en) 2005-08-01
TWI298327B (en) 2008-07-01
HK1091815A1 (zh) 2007-01-26
IS8267A (is) 2006-01-26
TNSN06063A1 (en) 2007-10-03
KR20060071404A (ko) 2006-06-26
OA13238A (en) 2006-12-13
IL173439A0 (en) 2006-06-11
MEP45308A (en) 2011-02-10
ZA200601526B (en) 2007-04-25
CR9834A (es) 2008-04-21
US7160888B2 (en) 2007-01-09
WO2005019215A1 (en) 2005-03-03
NL1026892C2 (nl) 2005-11-21
CN100422181C (zh) 2008-10-01
HN2004000319A (es) 2010-06-09
PE20051039A1 (es) 2005-12-12
EA009645B1 (ru) 2008-02-28
GT200500007A (es) 2005-10-24
AU2004266191A1 (en) 2005-03-03
CA2538915A1 (en) 2005-03-03
AR045386A1 (es) 2005-10-26
CN1839134A (zh) 2006-09-27
KR20070053364A (ko) 2007-05-23
EA200600294A1 (ru) 2006-08-25
KR100801794B1 (ko) 2008-02-05

Similar Documents

Publication Publication Date Title
ECSP066391A (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
UY28876A1 (es) Compuestos de morfolina sustituida y composiciones para el tratamiento de trastornos del sistema nervioso central
UY28150A1 (es) Agentes terapeuticos
UY28144A1 (es) Agentes terapéuticos
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
UY30314A1 (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
ECSP088366A (es) 1,2-diarilimidazoles para uso como moduladores de cb1
CR9407A (es) Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
UY27998A1 (es) Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia
CR10255A (es) "nuevas composiciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos"
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
UY28839A1 (es) Agentes terapeuticos
UY28656A1 (es) Derivados de indano heterocíclicos sustituidos y compuestos relacionados para el tratamiento de esquizofrenia
CR7735A (es) Piperizinas heterociclicas sustituidas para el tratamiento de la esquizofrenia
UY29308A1 (es) Derivado de quinolina, su uso, preparación y medicamento que lo contiene
UY28476A1 (es) (1,8) naftirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
UY29052A1 (es) Nuevos inhibidores de la recaptación de norepinefrina de quinoxalinona para el tratamiento de trastornos del sistema nervioso central
DOP2004001045A (es) Derivados de indano heterrociclicos sustituido y compuesto relacionados para el tratamiento de la esquizofrenia
DOP2003000709A (es) Piperazinas heterociclicas sustituidas para el tratamiento de la esquizofrenia